Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after <scp>HeartMate</scp> 3 left ventricular assist device implantation
No differences in frequency of bleeding or thromboembolic events were observed in this study between FXa versus aPTT cohorts after HM3 implantation. More longitudinal studies are warranted to determine whether or not one assay is superior to the other.
Authors
- Nir Y. Uriel (ORCID: https://orcid.org/0000-0003-2301-3587)
- Koji Takeda (ORCID: https://orcid.org/0000-0001-8263-1911)
- Paul Kurlansky (ORCID: https://orcid.org/0000-0003-2681-9885)
- Jonathan Hastie
- melana yuzefpolskaya (ORCID: https://orcid.org/0000-0003-4729-8943)
- Gabriel Sayer (ORCID: https://orcid.org/0000-0003-1701-1593)
- Andrew Eisenberger (ORCID: https://orcid.org/0000-0001-6846-5099)
- P.C. Colombo (ORCID: https://orcid.org/0000-0003-4977-3285)
- Iris Feng (ORCID: https://orcid.org/0000-0002-6494-126X)
- Yoshifumi Naka (ORCID: https://orcid.org/0000-0003-1808-7063)
- Melissa A. Hynds
- Christine G. Yang
- Tanner R. Powley
- Lauren D. Sutherland
Institutions
- Columbia University Irving Medical Center (US)
- Columbia University (US)
Publication Details
- Journal
- Artificial Organs
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1111/aor.14885
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00